Providence Pharmacy PGY2 Program at Providence Medical Group 2026

Follow

• 

  An Exploration of Positive Psychology Practices in an Integrated Primary Care Setting

  Rebecca Crowder

• 

  Optimizing Behavioral Health Integration in Primary Care through a Targeted Didactic

  Ravneet Dhaliwal, M.A., Behavioral Health Intern

• 

  Evaluating the Interrater Reliability for the Intern Selection Process Done at Providence Medical Group Psychology Training Program

  Vanoosheh Ferdousian, M.A.

• 

  Evaluation of Clinical Pharmacist-Led Ambulatory Blood Pressure Monitoring Service and its Impact on Hypertension Outcomes in a Primary Care Setting

  Ariel Ford, PharmD; Justin Bachman, PharmD, BCACP; and Abby Frye, PharmD, BCACP

  Abstract: Based on current hypertension treatment guidelines, ambulatory blood pressure monitoring (ABPM) is one of the preferred methods to obtain out-of office BP measurements for the diagnosis and management of hypertension. It is considered the gold-standard for identifying white-coat hypertension, masked hypertension, and resistant hypertension. ABPM is commonly underutilized due to cost and other factors, which has the potential to contribute to hypertension treatment disparities. In 2017, a pharmacist-led ABPM service was introduced at Providence Medical Group (PMG) at St. Vincent. During the first year of use at PMG at St. Vincent, 53 patients completed ABPM, and the results were positive: 87% of pharmacist recommendations were accepted and/or implemented and 84% of patients were at their HTN goal at follow-up. Since then, pharmacist-led ABPM services have been implemented at many other PMG primary care clinics in Oregon; however, the impact of this expansion has not been studied. The purpose of this study is to evaluate the impact of pharmacist-led ABPM services on hypertension outcomes in the primary care setting. This is a multi-center retrospective chart review that used a Slicer Dicer report to identify the total number of ABPM exams completed at PMG Oregon Primary Care clinics from April 1, 2024, to April 1, 2025. One hundred and fifty patients were randomly selected for data collection. Patients whose ABPM results were not evaluated by a clinical pharmacist or did not complete ABPM were excluded. Data collection will include baseline characteristics and demographics, reason for referral, baseline blood pressure, ABPM findings, relevant medication changes, pharmacist clinical intervention, and blood pressure findings at least six months after ABPM. Collected data will be used to assess whether pharmacist recommendations were implemented and the impact that recommendation had on blood pressure control. Results and conclusions will be shared upon completion of this clinical inquiry. (IRB exempt) Learning Objectives: Describe the impact of pharmacist-led ambulatory blood pressure monitoring services on hypertension outcomes Presentation Category: Ambulatory Care/Disease State Management

• 

  Assessment of medication adherence and clinical outcomes in diabetes patients After enrollment in a health-system medication assistance program

  Joshua Wood, PharmD

• 

  Analysis of Hospital Readmission among PACE Participants in Oregon

  Hanna Yoon, PharmD; Sharon Leigh, PharmD, BCPS; and Alyson Bell, PharmD

  Introduction: Older adults face an elevated risk of hospitalization-associated harms, including falls, cognitive decline, and functional loss. Unplanned readmissions affect 15%–30% of Medicare beneficiaries annually and contribute an estimated $12 billion in potentially preventable costs. For programs of All-Inclusive Care for the Elderly (PACE), understanding factors that contribute to repeat or medication-related hospitalizations is critical for improving patient care, and informing pharmacist-led interventions aimed at reducing avoidable admissions. Objective: This project seeks to identify trends and potentially preventable causes of hospital readmissions among PACE participants and to evaluate opportunities for targeted interventions. Methods: A retrospective chart review was conducted using data from EPIC and PACE internal systems. The study included Oregon PACE participants with more than one hospitalization between January 1 and December 31, 2024. Hospitalizations occurring before PACE enrollment and elective admissions were excluded. Results: A total of 583 admissions involving patients more than one hospitalization were initially identified. After applying exclusion criteria, 449 admissions among 160 patients were included. The mean age was 74 years, 107 (66.9%) were female, 63 (39.4%) resided in adult family homes, and 16 (10.0%) were receiving palliative care. Urinary tract infection was the most common discharge diagnosis (75 admissions, 16.7%), followed by heart failure (61 admissions, 13.6%). Medication-related causes accounted for 56 admissions (12.5%), most frequently involving central nervous system agents (16 admissions, 28.6%) and opioids (10 admissions, 17.9%). Admissions were evenly distributed by month with an average of 37 admissions per month; July had the highest number (45). Among the 449 admissions, 29 (6.5%) involved a fall prior to admission, 113 (25.2%) were 30-day readmissions, and 326 (72.6%) had at least one PACE encounter within 3 days prior to admission. The estimated total cost of hospitalization for these admissions was $7,237,500. Conclusion: Pharmacist-led interventions targeting urinary tract infection prevention, central nerve system medication optimization, and close follow-up may reduce preventable readmissions in PACE participants.